Abstract:Medicinal plants and products thereof are undoubtedly of great medicinal and economic importance; however, compared with conventional pharmaceutical preparations they also present a number of unique features and challenges. First, they are usually comprised of a complex mixture of compounds that can vary considerably even within the same species, depending on environmental (e.g., climate, altitude) and genetic factors. Second, sometimes different herbs are used as a mixture, which further complicates the composition of a sample. And finally, the compounds responsible for therapeutic effects are frequently unknown or can only partially explain a plant's usage. Quality control is therefore of utmost importance in any herbal product, from using authenticated plant material to the development of suitable analytical techniques for ensuring a finished product's consistency and efficacy. This special issue of Planta Medica is devoted to plant analysis, a field nearly as manifold and diverse as the array of compounds produced in (medicinal) plants themselves. The analyst not only has to allow for the particular chemical and physical properties of the compounds of interest but also needs to select the most promising analytical approach. Therefore any publication dealing with plant analysis should not be limited to the description of currently employed analytical techniques but also address the specific problems and challenges associated with the matrices investigated as well as indicate future trends and perspectives. The first manuscripts in this special issue aim to familiarize the reader with historical aspects of plant analysis and pinpoint several general aspects, such as the importance of reference compounds, the impact of sample preparations and the legal status of commercial products. Comparing the most important markets for herbal medications, which are Europe (and here especially Germany and France) and the United States, reveals significant differences in the legal understanding of these products. This explains the fact why they may be classified either as dietary supplements or as herbal medicinal products. Even though there may not be much difference for the consumer at first glance, these terms refer to two completely different product categories with different rules and regulations regarding quality control and efficacy claims. In the second and major part of this volume technical aspects and applications are described and discussed. This includes not only currently employed analytical techniques like thin-layer chromatography, high-performance liquid chromatography and capillary electrophoresis, but also innovative developments. The latter include, for example, the use of near infrared spectroscopy, metabolic fingerprinting and quantitative determinations based on nuclear magnetic resonance spectra. Last but not least recent analytical applications on Traditional Chinese Medicines, a currently booming product segment, are presented. By choosing such a broad approach to plant analysis we aim to provide a comprehensive summary of the current status quo and point to possible future trends and developments. Therefore this special issue of Planta Medica should not only be of interest to scientists already working in this field but also to others from related areas. The editors are grateful to the authors for their interesting contributions and to the reviewers for their valuable comments. We also would like to thank Prof. Matthias Hamburger and Prof. Luc Pieters for giving us the opportunity to serve as guest editors for this special issue of Planta Medica.

Basic Requirements and Framework Conditions of Real-World Data (RWD) on Herbal Medicinal Products

Clinical Pharmacology Applications of Real‐World Data and Real‐World Evidence in Drug Development and Approval–An Industry Perspective

Contribution of Real‐World Evidence in European Medicines Agency's Regulatory Decision Making

Consensus Statement on the Outcome of the European Herbal Health Products Summit – Which Way Forward?

Real-World Evidence: A Primer

Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process

Use of Real-World Data and Real-World Evidence in Rare Disease Drug Development: A Statistical Perspective

A national evaluation analysis and expert interview study of real-world data sources for research and healthcare decision-making

Rationalizing optimal dosing of phytotherapeutics for use in children: Current status - potential solutions - actions needed

Contemporary Practice and Considerations for Real-World Data Source Identification and Feasibility Assessment

Current regulations of Herbal medicines in the US and EU

Using Social Media as a Source of Real-World Data for Pharmaceutical Drug Development and Regulatory Decision Making

CURRENT STATUS AND CHALLENGES OF HERBAL DRUG DEVELOPMENT AND REGULATORY ASPECT: A GLOBAL PERSPECTIVE

Marketing Authorization Applications Made to the European Medicines Agency in 2018–2019: What was the Contribution of Real‐World Evidence?

Die Anwendung von Real-world-Evidenz in Entscheidungsprozessen der Arzneimittelregulation

Pesticide residues in herbal drugs: Evaluation of a database

Use of Real‐World Evidence to Drive Drug Development Strategy and Inform Clinical Trial Design

Medicinal plants and their preparations in the European market: Why has the harmonization failed? The cases of St. John's wort, valerian, ginkgo, ginseng, and green tea

The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety

Plant Analysis – State of the Art and Future Developments